{
  "id": 12835293,
  "title": "Oppenheimer reiterates Capricor stock rating on FDA data robustness",
  "url": "https://urgent.news/2026/10/08/oppenheimer-reiterates-capricor-stock-rating-on-fda-data-robustness",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-08T09:38:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/oppenheimer-reiterates-capricor-stock-rating-on-fda-data-robustness-93CH-4938276"
  },
  "original_language": "en",
  "account": null,
  "summary": "Oppenheimer has reaffirmed an Outperform rating on Capricor Therapeutics (NASDAQ:CAPR) following a company webinar that reviewed data submitted to the FDA. The rating implies significant upside potential based on the current stock price of $8.10, which has declined 74% over the past six months. The firm highlighted robustness in the HOPE-3 trial’s primary endpoint, with over 600 alternative analyses supporting a 1-point treatment effect over placebo for deramiocel efficacy on upper limb function. Additionally, integrated analyses from HOPE-2 and HOPE-3 show a 1.29 point PUL 2.0 benefit at Month 12 with a p-value of 0.0087, and favorable LVEF data in the ITT population and patients with cardiomyopathy. Oppenheimer believes the package has a higher likelihood of approval than the current stock price suggests, with a Fair Value of $10.54.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}